title: [Androgenetic alopecia in the man].
abstract: Androgenetic alopecia (AGA) occurs in approximately 40% of men at the age of 40 and 50% at 50, respectively. Especially for young men progressive hair loss can be distressing. Therefore, understanding of these patients' concerns is important for appropriate management. Current understanding of the pathophysiology of AGA mainly focuses on androgen metabolism as it affects hair growth. As a result, pharmacologic treatment has made considerable progress through the introduction of selective 5 alpha-reductase inhibition with finasteride. In placebo-controlled clinical trials in men with AGA, treatment with oral finasteride proved to be effective. Minoxidil is the only pharmacological substance for topical application with proven efficacy. So far, other treatment modalities have no proven efficacy in clinical trials, so that their use cannot be recommended. Options for advanced AGA not amenable to pharmacologic treatment are autologous hair transplantation and hair replacement, both of which have recently also made progress in terms of cosmetic appeal.
authors.affiliation: Dermatologische Klinik, UniversitätsSpital Zürich.
authors.forename: U
authors.initials: U
authors.lastname: Bader
authors.forename: R M
authors.initials: RM
authors.lastname: Trüeb
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000505:Alopecia / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D000728:Androgens / Q000502:physiology*; D018120:Finasteride / Q000627:therapeutic use; D006197:Hair / Q000637:transplantation; D018859:Hair Follicle / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008914:Minoxidil / Q000627:therapeutic use
chemical_list: D000728:Androgens; D018120:Finasteride; D008914:Minoxidil